In Silico Investigation of the Decline in Clinical Efficacy of Artemisinin Combination Therapies Due to Increasing Artemisinin and Partner Drug Resistance-Reference-Cited by-同舟云学术

In Silico Investigation of the Decline in Clinical Efficacy of Artemisinin Combination Therapies Due to Increasing Artemisinin and Partner Drug Resistance

Published:2018-12 Issue:12 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Zaloumis Sophie G.¹^ORCID,Cao Pengxing²,Dini Saber¹,Davenport Miles P.³,Cromer Deborah³,Khoury David S.³,Fowkes Freya J. I.¹⁴⁵⁶,McCaw James M.¹²,Simpson Julie A.¹

Affiliation:

1. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia

2. School of Mathematics and Statistics, University of Melbourne, Melbourne, Australia

3. Infection Analytics Program, The Kirby Institute, UNSW, Sydney, Australia

4. Burnet Institute, Melbourne, Australia

5. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia

6. Department of Infectious Diseases, Monash University, Melbourne, Australia

Abstract

Antimalarial treatment currently relies on an artemisinin derivative and a longer-acting partner drug. With the emergence of resistance to the artemisinin derivatives and the potential pressure this exerts on the partner drugs, the impact of resistance to each drug on efficacy needs to be investigated.

Funder

Department of Health | National Health and Medical Research Council

Department of Education and Training | Australian Research Council

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01292-18

Reference34 articles.

1. World Trade Report 2017

2. World Health Organization. 2015. Guidelines for the treatment of malaria, 3rd ed. World Health Organization, Geneva, Switzerland.